↓ Skip to main content

Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines

Overview of attention for article published in Journal of Molecular Medicine, November 2019
Altmetric Badge

Mentioned by

twitter
2 tweeters
Title
Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines
Published in
Journal of Molecular Medicine, November 2019
DOI 10.1007/s00109-019-01844-3
Pubmed ID
Authors

Zhidong Hu, Weimin Jiang, Ling Gu, Dan Qiao, Tsugumine Shu, Douglas B. Lowrie, Shui-Hua Lu, Xiao-Yong Fan

Abstract

In an earlier study, a novel Sendai virus-vectored anti-tuberculosis vaccine encoding Ag85A and Ag85B (SeV85AB) was constructed and shown to elicit antigen-specific T cell responses and protection against Mycobacterium tuberculosis (Mtb) infection in a murine model. In this study, we evaluate whether the immune responses induced by this novel vaccine might be elevated by a recombinant DNA vaccine expressing the same antigen in a heterologous prime-boost vaccination strategy. The results showed that both SeV85AB prime-DNA boost (SeV85AB-DNA) and DNA prime-SeV85AB boost (DNA-SeV85AB) vaccination strategies significantly enhanced the antigen-specific T cell responses induced by the separate vaccines. The SeV85AB-DNA immunization regimen induced higher levels of recall T cell responses after Mtb infection and conferred better immune protection compared with DNA-SeV85AB or a single immunization. Collectively, our study lends strong evidence that a DNA vaccine boost might be included in a novel SeV85AB immunization strategy designed to enhance the immune protection against Mtb. KEY MESSAGES: A heterologous prime-boost regimen with a novel recombinant SeV85AB and a DNA vaccine increase the T cell responses above those from a single vaccine. The heterologous prime-boost regimen provided protection against Mtb infection. The DNA vaccine might be included in a novel SeV85AB immunization strategy designed to enhance the immune protection against Mtb.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2019.
All research outputs
#11,166,985
of 14,083,335 outputs
Outputs from Journal of Molecular Medicine
#902
of 1,155 outputs
Outputs of similar age
#186,964
of 262,503 outputs
Outputs of similar age from Journal of Molecular Medicine
#8
of 14 outputs
Altmetric has tracked 14,083,335 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,155 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,503 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.